Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.
Procopio G, Chiuri VE, Giordano M, Alitto AR, Maisano R, Bordonaro R, Cinieri S, Rossetti S, De Placido S, Airoldi M, Galli L, Gasparro D, Ludovico GM, Guglielmini PF, Carella C, Nova P, Aglietta M, Schips L, Beccaglia P, Sciarra A, Livi L, Santini D; ABItude Study Group. Procopio G, et al. Among authors: galli l. ESMO Open. 2022 Apr;7(2):100431. doi: 10.1016/j.esmoop.2022.100431. Epub 2022 Apr 8. ESMO Open. 2022. PMID: 35405438 Free PMC article.
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
Ranzenigo M, Gianotti N, Galli L, Poli A, Mastrangelo A, Bruzzesi E, Chiurlo M, Nozza S, Bossolasco S, Spagnuolo V, Mancusi D, Termini R, Carini E, Lazzarin A, Castagna A. Ranzenigo M, et al. Among authors: galli l. Drug Des Devel Ther. 2022 Jun 27;16:1975-1982. doi: 10.2147/DDDT.S358976. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35783200 Free PMC article.
Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures.
Gagliardini R, Lorenzini P, Cozzi-Lepri A, Tavelli A, Borghi V, Galli L, Tagliaferri G, Maggiolo F, Mussini C, Castagna A, Monforte AD, Antinori A. Gagliardini R, et al. Among authors: galli l. J Glob Antimicrob Resist. 2023 Mar;32:158-163. doi: 10.1016/j.jgar.2022.11.010. Epub 2022 Nov 17. J Glob Antimicrob Resist. 2023. PMID: 36402369 Free article.
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
Galizzi N, Poli A, Galli L, Muccini C, Mastrangelo A, Dell'Acqua R, Maillard M, Bossolasco S, Cinque P, Lazzarin A, Castagna A, Gianotti N. Galizzi N, et al. Among authors: galli l. Int J Antimicrob Agents. 2020 Mar;55(3):105893. doi: 10.1016/j.ijantimicag.2020.105893. Epub 2020 Jan 9. Int J Antimicrob Agents. 2020. PMID: 31926287
Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infection.
Rinaldi F, Rolla S, Galli L, Poli A, Muccini C, Mastrangelo A, Tavano C, Lazzarin A, Bartoloni A, Castagna A. Rinaldi F, et al. Among authors: galli l. New Microbiol. 2020 Apr;43(2):55-57. Epub 2020 Apr 19. New Microbiol. 2020. PMID: 32310296 Free article.
1,149 results